You are here: Industry Insights > AstraZeneca

News List

AstraZeneca teams up with Accent Therapeutics for cancer therapies pharmaceutical-technology
June 05, 2020
The partners aim for therapeutics that act on RNA-modifying proteins (RMPs) to treat cancer.
FDA approves new indication for AstraZeneca’s heart disease drug Brilinta pharmaceutical-business-review
June 03, 2020
AstraZeneca has secured approval from the US Food and Drug Administration (FDA) for its Brilinta (ticagrelor) to minimise the risk of a first heart attack or stroke in high-risk patients with a heart disease known as coronary artery disease (CAD).
AstraZeneca’s heart disease drug Brilinta gets FDA approval pharmaceutical-technology
June 02, 2020
AstraZeneca has received approval from the US Food and Drug Administration (FDA) for Brilinta (ticagrelor) to decrease the risk of a first heart attack or stroke in high-risk patients suffering from coronary artery disease (CAD).
Tagrisso shows 'unprecedented' disease free survival in lung cancer pharmatimes
June 01, 2020
According to AstraZeneca, its EGFR inhibitor Tagrisso (osimertinib) has shown 'unprecedented disease-free survival' in the adjuvant treatment of patients with EGFR-mutated lung cancer.
AstraZeneca says it may consider exposing vaccine trial participants to virus expresspharma
June 01, 2020
The British drugmaker last week started phase 2 and 3 trials of the vaccine, looking to recruit around 10,000 adults and children in Britain.
Enhertu granted orphan drug designation in US for gastric cancer pharmaceutical-business-review
May 28, 2020
AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo)’s Enhertu (trastuzumab deruxtecan) has been granted Orphan Drug Designation (ODD) in the US for the treatment of patients with gastric cancer, including gastroesophageal junction cancer.
AZ links with ArcherDX to detect minimal residual disease in lung cancer patients pharmatimes
May 27, 2020
AstraZeneca is teaming up with genomic analysis group ArcherDX to use personalised cancer monitoring to detect minimal residual disease (MRD) in patients with early-stage non-small cell lung cancer (NSCLC).
Bevespi Aerosphere approved in China for patients with COPD americanpharmaceuticalreview
May 26, 2020
AstraZeneca’s Bevespi Aerosphere (glycopyrronium/formoterol fumarate) has been approved in China as a maintenance treatment to relieve symptoms in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
AstraZeneca Gets $1B from U.S. to Deliver COVID-19 Vax by Fall contractpharma
May 26, 2020
Aims to make potential COVID-19 vaccine AZD1222 widely accessible with first deliveries in September 2020.
AstraZeneca-Merck’s Lynparza gets US FDA nod for prostate cancer treatment expresspharma
May 21, 2020
The drug approval by the US regulator is for treating patients with a form of prostate cancer that could not be held back by standard hormone therapy.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 80 81 Next page